Clinical trial
Neramexane for Tinnitus
NCT00405886 · Merz Pharmaceuticals GmbH, Industry · Completed
Key facts
| NCT number | NCT00405886 |
|---|---|
| Title | Neramexane for Tinnitus |
| Official title | A Randomised, Double-Blind, Placebo-Controlled, Clinical Dose-Ranging Trial to Evaluate Efficacy and Safety of a NMDA Antagonist for Oral Administration in Patients With Subjective Tinnitus |
| Lead sponsor | Merz Pharmaceuticals GmbH, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Tinnitus |
| Intervention type | Drug |
| Interventions | Neramexane, Placebo |
| Enrollment | 431 |
| Start date | Oct 1, 2005 |
| Primary completion | Mar 1, 2007 |
| Completion | Mar 1, 2007 |
| First posted | Nov 30, 2006 |
| Last update posted | Mar 11, 2011 |
| Countries | Austria, Germany |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: